Skip to main content
. 2017 Feb;29(1):86–92. doi: 10.21147/j.issn.1000-9604.2017.01.10

3.

Comparison of median survival of CRS+HIPEC versus surgery alone

Treatment Case No. (Ref No.) Median survival (month) P
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.
CRS+HIPEC 34 (19) 11.0 0.046
17 (24) 11.0 0.0455
107 (25) 11.5 0.001
49 (26) 10.3 Not provided
Surgery alone 34 (19) 6.5 0.046
20 (24) 6.0 0.0455